These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For research use only.  Legal & Disclaimer

For research use only. Not for human use. All compounds supplied by Sequence Labs are intended exclusively for in vitro and preclinical research purposes.

Synthetic GHRH Analog · 44-Amino Acid Peptide

Tesamorelin Research Compound

Full-length GHRH(1-44) analog with trans-3-hexenoic acid N-terminal modification for enhanced stability. Supplied as lyophilized powder in research-grade vials, independently tested by Krause Analytical with full COA transparency. For research use only — not for human use.

5mg Vial 10mg Vial COA — Krause Analytical Reviewed: Sabrina Runbeck, PA-C Finnrick Pulse

Compound Overview

What Is Tesamorelin?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), the endogenous 44-amino acid hypothalamic peptide that regulates pulsatile GH secretion via the pituitary gland. Unlike truncated analogs such as sermorelin (GHRH(1-29)), tesamorelin retains the full-length 44-amino acid GHRH sequence — preserving the complete structural motif associated with GHRH receptor binding in preclinical research models.

The defining structural feature of tesamorelin is its trans-3-hexenoic acid modification at the N-terminus. This modification stabilizes the peptide against enzymatic degradation by dipeptidyl peptidase IV (DPP-IV) and other proteases that rapidly cleave native GHRH in physiological environments. This property makes tesamorelin a useful research tool for studying GHRH receptor biology under conditions where peptide stability is a confounding variable.

The distinction between full-length and truncated GHRH analogs is significant in receptor research. GHRH(1-29) retains primary receptor-binding capacity, but the C-terminal region of GHRH(1-44) is believed to influence receptor occupancy kinetics and downstream signaling amplitude — an area of ongoing preclinical investigation. Tesamorelin's full-length structure, combined with its N-terminal modification, provides a stable platform for studying these questions in animal models.

In preclinical literature, tesamorelin has been examined in connection with GH axis stimulation, IGF-1 pathway signaling, and adipose tissue biology in animal models. Published research has examined GHRH receptor activation, downstream pituitary signaling, and metabolic pathway effects across multiple preclinical settings. All Sequence Labs supply is classified strictly as a research compound — for in vitro and preclinical use only.

For Research Use Only · Not for Human Use
Technical Specifications
Compound Tesamorelin
Class Synthetic GHRH Analog
Structure Full-length GHRH(1-44)
Modification trans-3-Hexenoic acid (N-terminus)
Amino Acids 44
Mol. Formula C221H366N72O67S
Mol. Weight ~5135 Da
CAS Number 218949-48-5
Purity ≥99% (HPLC + MS verified)
Testing Lab Krause Analytical
Available Sizes 5mg · 10mg
Form Lyophilized Powder
Classification Research Compound Only

Research Background

Published Research Areas

Published research has examined tesamorelin across several interconnected areas of GHRH biology and metabolic pathway research in preclinical models. The following domains represent the primary areas of peer-reviewed investigation.

GHRH Receptor Binding Research

Published research has examined tesamorelin's binding affinity at GHRH receptors in pituitary cell lines and preclinical models. The trans-3-hexenoic acid modification provides a stable ligand for characterizing receptor occupancy and downstream cAMP/PKA signaling cascades in vitro.

GH Axis Stimulation in Preclinical Models

Published research has examined tesamorelin-mediated GH axis responses in rodent and primate preclinical models. Research has characterized pulsatile GH release patterns, concentration-response relationships, and pituitary responsiveness following GHRH analog exposure in various animal study designs.

Adipose Tissue Biology Research

Published research has examined adipose tissue biology in preclinical animal models following GHRH analog exposure, with particular attention to depot-specific differences in animal study settings. This line of research contributes to understanding GHRH signaling's role in metabolic pathway regulation in non-human models.

Lipid Metabolism Pathway Research in Animal Models

Published research has examined lipid metabolism pathway responses in animal models, exploring how GH axis activation via GHRH receptor agonism correlates with lipase activity, free fatty acid flux, and triglyceride metabolism in preclinical settings. Not studied or applicable in human subjects.

IGF-1 Axis Research

Published research has examined the IGF-1 axis downstream of GH stimulation in preclinical models exposed to GHRH analogs including tesamorelin. Research has characterized IGF-1 secretion kinetics, hepatic IGF-1 production pathways, and feedback regulation at the hypothalamic-pituitary axis in animal models.

Browse peer-reviewed tesamorelin GHRH research on PubMed: pubmed.ncbi.nlm.nih.gov/?term=tesamorelin+GHRH

GHRH Analog Research Context

Tesamorelin vs. Sermorelin vs. CJC-1295

All three are GHRH analogs studied for their ability to bind and activate the GHRH receptor in preclinical research settings. They differ in sequence length, structural modification, and half-life profile — each presenting distinct properties for GHRH receptor research.

Property Sermorelin
(GHRH(1-29))		 Tesamorelin
(GHRH(1-44) + mod)		 CJC-1295
(GHRH(1-29)-DAC)
Sequence GHRH(1-29) — truncated GHRH(1-44) — full-length GHRH(1-29) — truncated + DAC
N-terminal Modification None (native N-terminus) trans-3-Hexenoic acid None (DAC at Lys38)
Half-life Profile (Research) Short (~10–20 min in rodents) Extended vs. native GHRH (DPP-IV resistance) Prolonged (~6–8 days via albumin binding)
Amino Acid Length 29 amino acids 44 amino acids 29 amino acids
Receptor Binding Class GHRH-R agonist GHRH-R agonist GHRH-R agonist
Stability Mechanism Native — rapid clearance DPP-IV protection via N-terminal acyl group Albumin binding via Drug Affinity Complex
Primary Research Utility Short-burst GHRH-R activation in preclinical models Stable full-length GHRH-R research platform Sustained GH axis stimulation research
Sequence Labs Supply 5mg · 10mg 5mg · 10mg 5mg · 10mg

Sequence Labs Supply

Tesamorelin Research Samples

Lyophilized tesamorelin research compound supplied in 5mg and 10mg vials. Every batch independently tested by Krause Analytical. For research use only — not for human use.

Research Sample
5mg Vial
~$55
  • Lyophilized tesamorelin — ≥99% purity
  • HPLC + Mass Spec verified
  • Tested by Krause Analytical
  • COA available on request
  • Reviewed: Sabrina Runbeck, PA-C
  • Finnrick Pulse fulfillment
Inquire — 5mg
Research Sample — Most Popular
10mg Vial
~$95
  • Lyophilized tesamorelin — ≥99% purity
  • HPLC + Mass Spec verified
  • Tested by Krause Analytical
  • COA available on request
  • Reviewed: Sabrina Runbeck, PA-C
  • Finnrick Pulse fulfillment
Inquire — 10mg
Testing Lab
Krause Analytical
Catalog Reviewer
Sabrina Runbeck, PA-C
Fulfillment
Finnrick Pulse

Laboratory Reference

Reconstitution Reference

Standard laboratory protocol reference for introducing solvent to lyophilized tesamorelin research samples. For research use only — not for human use.

Reconstitution Protocol — Research Use Only Not for Human Use
1
Prepare Solvent
Use bacteriostatic water (sterile water for injection containing 0.9% benzyl alcohol) as the recommended reconstitution solvent for research-grade tesamorelin samples.
2
Introduce Solvent
Introduce solvent slowly along the inner vial wall using a sterile syringe and needle. Avoid directing the solvent stream directly onto the lyophilized pellet to minimize foaming and ensure uniform dissolution.
3
Gentle Mixing
Gently swirl — do not vortex — the research sample vial until the lyophilized powder is fully dissolved. The resulting solution should appear clear and colorless.
4
Storage
Store reconstituted research samples according to your laboratory protocol. Lyophilized tesamorelin is typically stored at −20°C to −80°C; reconstituted samples should be stored at 4°C and used within the timeframe specified in your research protocol.
Research Use Only — Not for Human Use. This reconstitution reference is provided solely for in vitro laboratory and preclinical research settings. Tesamorelin supplied by Sequence Labs is not a pharmaceutical product and is not intended for use in humans under any circumstances. These statements have not been evaluated by the FDA. This information does not constitute medical or clinical guidance.

Frequently Asked Questions

Common questions about tesamorelin as a GHRH analog research compound.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is a full-length 44-amino acid peptide incorporating the complete GHRH(1-44) sequence, with a trans-3-hexenoic acid group linked to its N-terminus to confer enhanced resistance to enzymatic degradation. Its CAS number is 218949-48-5 and molecular weight is approximately 5135 Da (molecular formula C221H366N72O67S). Sequence Labs supplies tesamorelin as a research compound in lyophilized form for in vitro and preclinical research use only.
Tesamorelin is a full-length GHRH(1-44) analog — retaining all 44 amino acids of the native GHRH sequence — with a trans-3-hexenoic acid N-terminal modification that stabilizes the peptide against DPP-IV-mediated cleavage. Sermorelin is a truncated analog (GHRH(1-29)) that preserves primary GHRH receptor-binding capacity but lacks the C-terminal region of the full-length sequence. CJC-1295 is also a truncated GHRH(1-29) analog but incorporates a Drug Affinity Complex (DAC) modification that enables reversible albumin binding, substantially extending its half-life profile in research models to approximately 6–8 days. Each analog presents a distinct structural and pharmacokinetic profile for GHRH receptor and GH axis research.
Published research has examined tesamorelin in connection with: (1) GHRH receptor binding mechanisms and downstream pituitary signaling in cell and tissue models; (2) GH axis stimulation in preclinical rodent and primate models; (3) adipose tissue biology in animal studies; (4) lipid metabolism pathway responses in animal models; and (5) IGF-1 axis signaling downstream of GH release. Sequence Labs supplies tesamorelin strictly as a research compound for in vitro and preclinical use only — not for human subjects research or any clinical application.
Sequence Labs offers tesamorelin research samples in 5mg (~$55) and 10mg (~$95) vials. Each vial contains lyophilized tesamorelin at ≥99% purity, independently tested by Krause Analytical via HPLC and mass spectrometry. A Certificate of Analysis (COA) is available for every batch. Contact us to inquire or place an order.
For laboratory research purposes, introduce bacteriostatic water (sterile water with 0.9% benzyl alcohol) as the solvent by directing it slowly along the inner wall of the vial using a sterile syringe. Gently swirl — do not vortex — until the lyophilized powder dissolves completely. Store reconstituted research samples per your laboratory protocol; typically at 4°C for short-term use. This reference is provided for in vitro and preclinical laboratory settings only. For research use only — not for human use.
No. Tesamorelin supplied by Sequence Labs is strictly for research use only — not for human use. It is not a pharmaceutical product, not a drug product, and has not been evaluated by the FDA for any consumer, clinical, or human application in the form supplied. By purchasing from Sequence Labs, the buyer confirms they are a qualified researcher or licensed professional acquiring this compound exclusively for in vitro or preclinical research under appropriate laboratory conditions and oversight.

Inquire About Tesamorelin Research Supply

HPLC + MS verified by Krause Analytical. 5mg and 10mg research samples. COA on every batch. For research use only.

Browse All Research Compounds Sermorelin Research Page Contact Sequence Labs